Jessica Tassan
Stock Analyst at Piper Sandler
(1.02)
# 3,972
Out of 5,182 analysts
87
Total ratings
28%
Success rate
-13.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Overweight | $101 → $99 | $80.98 | +22.25% | 7 | Mar 31, 2026 | |
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $284.92 | +29.86% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $6.00 | +50.00% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $24.57 | +70.94% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $45.51 | +7.67% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $44.74 | +34.11% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $21.90 | +36.99% | 6 | Jan 6, 2026 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $18.04 | +38.58% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $366.77 | +13.70% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $9.42 | +260.93% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.62 | +397.24% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.34 | +199.63% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $23.49 | +266.11% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $229.72 | +18.41% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $6.25 | +28.00% | 3 | May 23, 2025 |
CVS Health
Mar 31, 2026
Maintains: Overweight
Price Target: $101 → $99
Current: $80.98
Upside: +22.25%
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $284.92
Upside: +29.86%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $6.00
Upside: +50.00%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $24.57
Upside: +70.94%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $45.51
Upside: +7.67%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $44.74
Upside: +34.11%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $21.90
Upside: +36.99%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $18.04
Upside: +38.58%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $366.77
Upside: +13.70%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $9.42
Upside: +260.93%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.62
Upside: +397.24%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.34
Upside: +199.63%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $23.49
Upside: +266.11%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $229.72
Upside: +18.41%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $6.25
Upside: +28.00%